Tailored pre-miRNA-107 administration. Throughout the experiment, authors explored the effectiveness and efficiency of cationic lipid NPs in delivering pre-miRNA-107 (LNP-pre-miRNA-107) targeting HNSCC tumors both in-vitro and in-vivo. miRNA-107 distribution into HNSCC cells was more than 80,000 times higher with LNP/pre-miRNA-107 than with normal pre-miRNA-107. After LNP/pre-miRNA-107 administration, the expression of HIF1-β, CDK6, and PKC was reduced compared to normal pre-miRNA-107. The gene discussed is ARNT; the disease is head and neck squamous cell carcinoma.